Precision Medicine In Acute Myeloid Leukaemia
Main Article Content
Abstract
Precision medicine also known as personalised or individualised medicine is an innovative method that integrates genomic, environmental, and lifestyle data to drive medical care decisions. Precision medicine aims to give more precise approaches to illness prevention, diagnosis, and treatment. Precision medicine has revolutionized the treatment and diagnosis of acute myeloid leukaemia, which is mainly based on chemotherapy and personalised techniques according to the molecular and genetic profile and targeted therapy . For almost every kinds of AML chemotherapy is considered as the primary treatment, however it can also be utilised in other treatments. Acute promyelocytic leukaemia (APL) belongs to the sub category of acute myeloid leukaemia that receives distinct treatment. AML treatment should begin as soon as possible following diagnosis since it can progress rapidly. A mutation is present in the FLT3 gene of the Leukaemia cells. Some newer medications specifically target cells that have this gene alteration. FLT3 inhibitors like midostaurin (Rydapt), quizartinib (Vanflyta), and gilteritinib (Xospata) are now approved to treat patients with acute myeloid leukaemia cells that have a FLT3 mutation. The importance of understanding leukemogenesis at the molecular level through genetic sequencing has led in prognostic assessments and the use of targeted therapies. For the identification of the best treatments, mutation analysis using Next Generation Sequencing is essential
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Döhner, H., Wei, A.H. and Löwenberg, B., 2021. Towards precision medicine for AML. Nature reviews Clinical oncology, 18(9), pp.577-590.
Burd, A., Levine, R.L., Ruppert, A.S., Mims, A.S., Borate, U., Stein, E.M., Patel, P., Baer, M.R., Stock, W., Deininger, M. and Blum, W., 2020. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nature medicine, 26(12), pp.1852-1858.
Megías-Vericat, J.E., Martínez-Cuadrón, D., Solana-Altabella, A. and Montesinos, P., 2020. Precision medicine in acute myeloid leukemia: where are we now and what does the future hold?. Expert Review of Hematology, 13(10), pp.1057-1065.
Marconi, G., Guolo, F., Nanni, J. and Papayannidis, C., 2023. Precision medicine for acute myeloid leukemia. Frontiers in Oncology, 13, p.1233757.
Collins, F.S. and Varmus, H., 2015. A new initiative on precision medicine. New England journal of medicine, 372(9), pp.793-795.
Guo, Y., Wang, W. and Sun, H., 2022. A systematic review and meta-analysis on the risk factors of acute myeloid leukemia. Translational Cancer Research, 11(4), p.796.
Albrecht, T.A., 2014, May. Physiologic and psychological symptoms experienced by adults with acute leukemia: an integrative literature review. In Oncology nursing forum (Vol. 41, No. 3, p. 286). NIH Public Access.
Estey, E. and Döhner, H., 2006. Acute myeloid leukaemia. The Lancet, 368(9550), pp.1894-1907.
Burnett, A.K., 2012. Treatment of acute myeloid leukemia: are we making progress?. Hematology 2010, the American Society of Hematology Education Program Book, 2012(1), pp.1-6.
Zhang, D., Zhu, Y., Jin, Y., Kaweme, N.M. and Dong, Y., 2021. Leukapheresis and hyperleukocytosis, Past and future. International Journal of General Medicine, pp.3457-3467.
Stubbins, R.J., Francis, A., Kuchenbauer, F. and Sanford, D., 2022. Management of acute myeloid leukemia: A review for general practitioners in oncology. Current Oncology, 29(9), pp.6245-6259.
O'Donnell, M.R., Tallman, M.S., Abboud, C.N., Altman, J.K., Appelbaum, F.R., Arber, D.A., Bhatt, V., Bixby, D., Blum, W., Coutre, S.E. and De Lima, M., 2017. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 15(7), pp.926-957.
Tefferi, A. and Letendre, L., 2012. Going beyond 7+ 3 regimens in the treatment of adult acute myeloid leukemia. J Clin Oncol, 30(20), pp.2425-2428.
Totiger, T.M., Ghoshal, A., Zabroski, J., Sondhi, A., Bucha, S., Jahn, J., Feng, Y. and Taylor, J., 2023. Targeted Therapy Development in Acute Myeloid Leukemia. Biomedicines, 11(2), p.641.
Grunwald, M.R. and Levis, M.J., 2013. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. International journal of hematology, 97, pp.683-694.
Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol. 2017;18:1061-1075.
Cooper, G. and Adams, K., 2022. The cell: a molecular approach. Oxford University Press.
Patel, N., RIch, B.J., Patel, S., Watts, J.M., Benveniste, R., Abramowitz, M., Markoe, A., Eichberg, D.G., Komotar, R.J., De La Fuente, M. and Pasol, J., 2021. Emergent radiotherapy for leukemia-induced cranial neuropathies refractory to intrathecal therapy. Cureus, 13(5).
Bär, I., Ast, V., Meyer, D., König, R., Rauner, M., Hofbauer, L.C. and Müller, J.P., 2020. Aberrant bone homeostasis in AML is associated with activated oncogenic FLT3-dependent cytokine networks. Cells, 9(11), p.2443.
Nair, R., Salinas-Illarena, A. and Baldauf, H.M., 2021. New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia, 35(2), pp.299-311.
Ungewickell, A. and Medeiros, B.C., 2012. Novel agents in acute myeloid leukemia. International journal of hematology, 96, pp.178-185.
Reville, P.K. and Kadia, T.M., 2021. Maintenance therapy in AML. Frontiers in Oncology, 10, p.619085.
Senapati, J., Kadia, T.M. and Ravandi, F., 2023. Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica, 108(9), p.2289.
Finn, L., Dalovisio, A. and Foran, J., 2017. Older patients with acute myeloid leukemia: treatment challenges and future directions. Ochsner Journal, 17(4), pp.398-404.
Palmieri, R., Paterno, G., De Bellis, E., Mercante, L., Buzzatti, E., Esposito, F., Del Principe, M.I., Maurillo, L., Buccisano, F. and Venditti, A., 2020. Therapeutic choice in older patients with acute myeloid leukemia: a matter of fitness. Cancers, 12(1), p.120.
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424-447.
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F.R., Büchner, T., Dombret, H., Ebert, B.L., Fenaux, P., Larson, R.A. and Levine, R.L., 2017. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood, The Journal of the American Society of Hematology, 129(4), pp.424-447.
Khan, M., Mansoor, A.E.R. and Kadia, T.M., 2017. Future prospects of therapeutic clinical trials in acute myeloid leukemia. Future Oncology, 13(6), pp.523-535.
Kantarjian, H., 2016. Acute myeloid leukemia--major progress over four decades and glimpses into the future. American Journal of Hematology, 91(1), pp.131-145.
Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M. and Ravandi, F., 2021. Acute myeloid leukemia: current progress and future directions. Blood cancer journal, 11(2), p.41.
Short, N.J. and Ravandi, F., 2016. Acute myeloid leukemia: past, present, and prospects for the future. Clinical Lymphoma Myeloma and Leukemia, 16, pp.S25-S29.